Licensing status

Publication and contact information


Alzheimer's disease (AD)

Glucagon-like peptide 1 (GLP-1)

Mouse studies suggest a GLP-1 cleavage product could help treat AD. In brain slices from an AD mouse model, pretreatment with the GLP-1 cleavage product GLP-1(9-36)amide restored hippocampal synaptic plasticity and normalized levels of mitochondria-derived superoxide, which is elevated by b-amyloid (Ab). In a mouse model of AD, GLP-1(9-36)amide
decreased learning and memory deficits compared with vehicle control without altering amyloid precursor protein (APP) or Ab levels. Next steps could include testing GLP-1(9-36)amide in additional animal models of AD.

SciBX 5(41); doi:10.1038/scibx.2012.1090
Published online Oct. 18, 2012

Patent and licensing status unavailable

Ma, T. et al. J. Neurosci.; published online Oct. 3, 2012;
Contact: Eric Klann, New York University, New York, N.Y.